Back

Factors prohibiting progression to prostanoid therapy in patients with pulmonary arterial hypertension and CTEPH who remain in functional class III or above despite maximal oral therapy

27 August 2016 (00:00 - 00:00)
Organised by:
Congress Presentation Part of: Poster session 3 - Chronic pulmonary hypertension Chronic pulmonary hypertension ESC Premium Access ESC Congress 2016

About the speaker

Photo
Doctor Hebah Nashat

Royal Brompton Hospital, London (United Kingdom of Great Britain & Northern Ireland)

15 More presentations in this session

Presentation thumbnail
Experience in the pulmonary arterial hypertension management over 30 years: insights of a national reference center.
Doctor C. Quezada-Loaiza (Madrid, ES)
Abstract Slides
Presentation thumbnail
Lung transplantation for pulmonary arterial hypertension, the multidisciplinary approach from an expert center.
Doctor C. Quezada-Loaiza (Madrid, ES)
Abstract Slides
Presentation thumbnail
Effects of sildenafil in patients with persistent pulmonary hypertension after left prosthetic valvular replacement at rest and during dobutamine stress according to the hemodynamic phenotype
Associate Professor R. Aguilar Torres (Madrid, ES)
Abstract Slides
Presentation thumbnail
Initial combination with bosentan and sildenafil as compared with initial monotherapy with the same drugs in patients with pulmonary arterial hypertension: a case-control, multicentre study
Professor M. Palazzini (Bologna, IT)
Abstract Slides
Presentation thumbnail
Effect of calcium channel blockers on exercise capacity in idiopathic pulmonary arterial hypertension responding to acute pulmonary vasoreactivity testing
Mr Y. Tang (Beijing, CN)
Abstract Slides

Access the full session

Session thumbnail
Poster session 3 - Chronic pulmonary hypertension

The Event

Event poster

ESC Congress 2016

27 August - 31 August 2016

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources